TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.
The fully operational Individual Access Services (IAS) solution under TEFCA will deliver on the promise of truly connected healthcare by giving patients and providers...
Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025
Initiated ALKAZAR...
VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed...
New direct admission program offers eligible students a streamlined pathway to higher education
RALEIGH, N.C., Aug. 6, 2025 /PRNewswire/ -- Starting this fall, more than 62,000 North...
Deal with Kell Kapital Partners Sets Foundation for Nationwide and Global Expansion of HydrogenXT's Clean Fuel & Electricity Network
HOUSTON, Aug. 5, 2025 /PRNewswire/ -- HydrogenXT,...